AspenBio Pharma (APPY) should be close to completing patient enrollment in its 510(k) clinical trial for AppyScore based on its previous update in early September when the trial had reached the half-way point in terms of enrolling patients. AppyScore is the world's first blood-based diagnostic tool for human appendicitis and APPY expects to file the 510(k0 before year-end with potential approval in early 2009.
Steve Ballmer states that a Microsoft buyout of Yahoo! would still make sense economically, but the buyout price is uncertain since the original deal was rebuffed by YHOO at $33 per share. However, Carl Icahn appeared on Fast Money last night and stated that a deal with MSFT would get done in some form. With YHOO touching lows near $11 earlier today, the pressure is on for some type of deal with MSFT and Microsoft has over $20B in cash while Yahoo's market cap is now less than half when the original deal was proposed.
Steve Ballmer states that a Microsoft buyout of Yahoo! would still make sense economically, but the buyout price is uncertain since the original deal was rebuffed by YHOO at $33 per share. However, Carl Icahn appeared on Fast Money last night and stated that a deal with MSFT would get done in some form. With YHOO touching lows near $11 earlier today, the pressure is on for some type of deal with MSFT and Microsoft has over $20B in cash while Yahoo's market cap is now less than half when the original deal was proposed.
$13.45 (10/16/08)
